Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers
Sponsor: QPS Holdings LLC
Listed as NCT03376529, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by QPS Holdings LLC, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Feb 2023 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- QPS Holdings LLC
- Simbec Research
- Spero Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .